Blood and image markers for ECP response in lung transplant CLAD
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study looks at whether blood tests and MRI scans can predict how well ECP (a blood-filtering treatment) works for people with CLAD after a lung transplant. If you’ve been prescribed ECP for CLAD and haven’t had it before, you may be able to help researchers find better ways to tailor treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 7 years old and have had a lung transplant (one or both lungs).
- You have been diagnosed with CLAD (a chronic condition that affects transplanted lungs) and your doctor has prescribed ECP treatment.
- You have not received ECP before.
- You have not received certain immune-suppressing drugs (anti-thymocyte globulin within 3 months or alemtuzumab within 12 months).
- If taking part in the MRI part of the study, you have no metal implants, claustrophobia, or seizure disorder, and no allergy to gadolinium or severe kidney problems.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
This study checks long-term health and well-being in people who previously joined a lung transplant research study. It may help doctors understand long-term changes after transplant and improve future care.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
Hear when a new Lung Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.